Flibanserin (hydrochloride) (propan-2-ol) (hydrate)

Flibanserin (BIMT-17) hydrochloride (propan-2-ol) hydrate is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin hydrochloride (propan-2-ol) hydrate binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin hydrochloride (propan-2-ol) hydrate shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research[1]-[5].

Product Specifications

Product Name Alternative

BIMT-17 (hydrochloride) (propan-2-ol) (hydrate) ; BIMT-17BS (hydrochloride) (propan-2-ol) (hydrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/flibanserin-hydrochloride.html

Purity

99.96

Solubility

10 mM in DMSO

Smiles

O=C1NC2=C(N1CCN3CCN(CC3)C4=CC=CC(C(F)(F)F)=C4)C=CC=C2.CC(O)C.Cl.[0.5].O.[0.5]

Molecular Formula

C20H22ClF3N4O.0.5C3H8O.0.5H2O

Molecular Weight

465.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Fayed M, et al. Insights into Flibanserin Oxidative Stress Degradation Pathway: In Silico – In Vitro Toxicity Assessment of Its Degradates[J]. New Journal of Chemistry, 2021. |[2]Invernizzi RW, et al. A potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT (1A) receptors. Br J Pharmacol. 2003 Aug;139 (7) :1281-8. |[3]Gelez H, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl) . 2013 Dec;230 (4) :639-52. |[4]Podhorna J, et al. Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety. Br J Pharmacol. 2000 Jun;130 (4) :739-46. |[5]Gelman F, et al. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis. 2017 Jan;8 (1) :16-25.